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Abstract: Background: Hepatitis C virus (HCV) contains a (+) ssRNA genome with highly 
conserved structural, functional RNA domains, many of them with unknown roles for the 
consecution of the viral cycle. Such genomic domains are candidate therapeutic targets. This 
study reports the functional characterization of a set of aptamers targeting the cis-acting 
replication element (CRE) of the HCV genome, an essential partner for viral replication and 
also involved in the regulation of protein synthesis. Methods: Forty-four aptamers were 
tested for their ability to interfere with viral RNA synthesis in a subgenomic replicon system. 
Some of the most efficient inhibitors were further evaluated for their potential to affect the 
recruitment of the HCV RNA-dependent RNA polymerase (NS5B) and the viral translation 
in cell culture. Results: Four aptamers emerged as potent inhibitors of HCV replication by 
direct interaction with functional RNA domains of the CRE, yielding a decrease in the HCV 
RNA levels higher than 90%. Concomitantly, one of them also induced a significant increase 
in viral translation (>50%). The three remaining aptamers efficiently competed with the 
binding of the NS5B protein to the CRE. Conclusions: Present findings confirm the potential 
of the CRE as an anti-HCV target and support the use of aptamers as molecular tools for 
investigating the functionality of RNA domains in viral genomes. 
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1. Introduction 
The hypothesis of an all-RNA based world inspired the recreation of the natural molecular selection and 
evolution processes in a test tube, with the aim of isolating nucleic acids with diverse activities. These 
efforts yielded the identification of the so-called aptamers, oligonucleotides able to recruit a wide variety 
of ligands [1,2]. Aptamers are isolated from a SELEX (Systematic Evolution of Ligands by Exponential 
enrichment) process, which consists on iterative sets of synthesis, binding, positive selection, and 
amplification steps over a randomized oligonucleotide pool. The resulting population is enriched in 
those molecules able to bind to the desired target molecule. The highly dynamic folding of nucleic acids 
is the key to understand the specific and efficient interaction of aptamers to their cognate target, thus 
demonstrating the versatility and flexibility of nucleic acids. 
Potential application of aptamers is an expanding field (for a review, see [3]). Since they can be easily 
synthesized and chemically modified, aptamers have emerged as attractive and feasible alternatives to 
small molecule and antibody-based therapies and diagnostic applications. Their features include high 
affinity and specificity, easy and large-scale synthesis by chemical methods, pharmaceutical versatility, 
and low immunogenicity [3]. The clinical value of aptamers has gained increasing relevance in the 
Virology field during last years. In this context, aptamers have been postulated not only as antiviral or 
biosensors, but also as tools for deciphering the molecular biology processes that govern the viral 
cycles of different viruses [4]. 
The isolation of aptamers directed against different protein targets of the hepatitis C virus (HCV) 
has been largely described [5]. The HCV belongs to the Flaviviridae family and is responsible for a 
worldwide health threat, infecting more than 180 million people (WHO data). Current treatments based 
on the combination of α-interferon with direct-acting antivirals (DAAs) targeting the viral protease NS3 
are partially effective due to the appearance of resistant viral variants [6,7], a common problem for the 
control of viral infections. Thus, searching for novel drugs and targets is a major goal. In this context,  
a deep knowledge of the molecular biology of the virus is also a requisite for developing effective 
antiviral compounds. 
The HCV genome is a (+) polarity, single-stranded RNA (ssRNA) molecule of ~9600 nts, which 
encodes a single open reading frame (ORF) flanked by untranslated regions (UTRs) (Figure 1A) [8,9]. 
These UTRs contain highly conserved domains, both in sequence and in secondary structure, which are 
essential for viral replication, translation and infectivity [10–16]. Conserved functional RNA domains 
have also been identified within the coding region, such as the cis-acting replication element (CRE) in 
the 3′ end of the coding region (Figure 1) [17–19]. The CRE is defined by three stem-loops, 5BSL3.1, 
5BSL3.2 and 5BSL3.3 [19] (Figure 1). While the role of the 5BSL3.1 and 5BSL3.3 domains is still 
unclear [20], the 5BSL3.2 domain (also named SL9266) has been largely studied. It consists of two G-C 
rich helices connected by an eight-base internal loop, and capped by a 12-base apical loop (Figure 1B) [19]. 
The preservation of both the sequence and the architecture of 5BSL3.2 is critical for efficient HCV 
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replication [20,21] and the regulation of viral protein synthesis [22]. These functional features depend on 
the establishment of long-distant RNA-RNA interactions with other genomic RNA domains (Figure 1A). 
(i) The 5BSL3.2 apical loop is complementary to the apical loop of the 3′SLII within the 3′X-tail [21], 
their resulting kissing-loop interaction is required for efficient viral RNA synthesis in cell culture [21]; 
(ii) whereas the internal loop of the 5BSL3.2 domain may swap between two mutually exclusive contacts: 
one with the apical loop of the IIId subdomain of the IRES region [23]; and the second one with the Alt 
region placed upstream of the CRE [24]. Both interactions are equally probable and show dissociation 
constants in the same range [25]. Therefore, by switching from one contact to another, 5BSL3.2 could 
promote conformational rearrangements, not only in the directly involved residues and surrounding areas, 
but also, in an indirect manner, in the rest of the functional partners that compose this network [26–28]. 
In addition, the 5BSL3.2 domain interacts with viral and host protein factors [29–31]. All these data 
support the idea that the 5BSL3.2 domain is a key player in the maintenance of the proper balance 
between different stages of the infective cycle, which is a critical issue for viral fitness. Therefore, it can 
be considered as an interesting target for new therapeutic approaches against HCV. Extensive work is yet 
required in these areas. 
We had previously reported the isolation of a collection of RNA aptamers targeting the CRE region 
of the HCV genome [32]. Some of these selected compounds were shown to interact with the 5BSL3.2 
domain and to promote an inhibition of the viral replication of ~50% in cell culture [33]. The present 
study describes the functional characterization of a complete set of the previously isolated anti-CRE 
aptamers. From this screening, four molecules have emerged as efficient inhibitors of viral replication, 
leading to a robust decrease in viral RNA synthesis, close to a 95%. The selected aptamers contain 
sequence motifs targeting the highly conserved 5BSL3.2 domain and/or the stem-loop harboring the 
translation stop codon. They efficiently bind to the CRE region and promote changes in its functionality, 
either at the translational level or at the recruitment of the viral RNA-polymerase. Taken together, our 
findings support the use of the CRE as an efficient antiviral target and highlight the potential of aptamers 
as molecular tools for understanding the biological role of functional RNA domains in viral genomes. 
 
(A) 
Figure 1. Cont. 
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(B) 
Figure 1. Structural organization of the HCV RNA genome. (A) Detailed diagram of the 
secondary structure proposed for the 5′ and 3′ ends of the HCV RNA including functional 
domains involved in the establishment of long-range RNA-RNA interactions. The minimal 
region required for the IRES activity is indicated. The architecture of the 3′ end of the viral 
genomic RNA is organized into two well-defined structural elements: the CRE region and 
the 3′X-tail. Translation start and stop codons are indicated by arrows. The grey solid lines 
identify long-distance RNA-RNA contacts involving the IRES, the CRE, the Alt, and the 
3′X-tail regions. HV, hypervariable region; ORF, open reading frame; (B) The sequence 
and the secondary structure for the HCV CRE region. Nucleotides complementary to the 
consensus sequences of the selected aptamers are indicated by different colors according to 
the consensus group [34]. Numbers refer to the nucleotide positions of the HCV Con1 isolate 
(GenBank accession number AJ238799). 
2. Results and Discussion 
2.1. Inhibition of HCV Replication by a Collection of RNA Aptamers Targeting the HCV CRE Region 
It had been previously observed that a small set of aptamers targeting the HCV CRE region interfered 
with viral replication in cell culture [32,34], pointing to the CRE as a potential antiviral target. To go 
further on this hypothesis, a wide and representative set containing forty four different aptamers 
isolated for their binding ability to the CRE (see Table 1) [32] was assayed for their capacity to affect 
HCV replication. For that purpose, Huh-7 cells bearing a dicistronic selectable subgenomic replication 
construct derived from HCV-1b genotype (Huh-7 NS3-3′ET) [35,36] were transfected with the different 
aptamers independently. Total RNA was extracted 18 h post-transfection and the relative amount of 
the subgenomic HCV RNA was monitored by quantitative RT-PCR, as described in the Experimental 
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Section. Transfection with a non-related small RNA molecule, RNA80, was used as a control experiment 
for data calibration [37,38]. 
Table 1. Aptamers used in this study. 
Aptamer SEQUENCE (5′→3′) GROUP 
P6-1 CGUGGACGAGAGCUGGUAGUGUGUGGCGAU 1   4  
P6-2 GCUGCUGUUACGUACUAAGGUGCGGCGGGG     5 
P6-6 CGGCUCUGGAUGGCGCUGUUUGUGUGUGGU    4  
P6-8 CAUUGUGCGACUGGGAGAGGGCGUGUCCG   3   
P6-19 CGUCCCGGCUGCGACAGGAUGGGGACAUGG  2    
P6-20 CAACGUGGCGAUGGCGUGUGUACGAUGUGG    4  
P6-23 CGUGUGCGCAGUGGGCAUCUGCGGACAGGG 1  3 4  
P6-43 GCAUCGGUGGGUAUUGCAGUGCCCGGCUGU  2 3   
P6-44 CGCGGCUUUGGGGACGUUAGCCAUCUGAUG     5 
P6-45 CGUGUGUGCUGGCUAGUGGUGAGUCCGG 1   4  
P6-50 CGGAGGUUGUGUGGGGGACGUCUGUUGUGC  2  4 5 
P6-53 CAGGUGGUGUUAGUUACGCGUAGGCGUGCC 1     
P6-57 GCGGCCUGCGAUCUGGAUGCUGCGUGGGCC   3   
P6-64 CCGAGGUGGCUGGGGACAGCAGGAGGAGCG 1 2    
P6-76 GGCAGCUCUAGAGGGGGCGUAAUCGGCUCG   3   
P6-77 GUGCUUGCGGUGUUGAGCCCAGCGGUAGUG 1     
P6-78 GGUACGGCAUGGCGCUACGGCUGGAUCGUG  2    
P6-79 GCUAUGGUGGCCUGGUCCGUCGGGGGGCCG 1    5 
P6-80 CGCUAGUGUGGCGUGUUGCAGUAGGCAGAG    4  
P6-81 CAGGAUGAGUACUGGGCUCCUCGGCGUUGG   3   
P6-82 GUGUGUAUGCAUUGACGGACGACUGGCCGG    4  
P6-83 GGUGGAUUGGUGACCUUUGUGCUACGGGCA 1  3   
P6-84 CCCUGUGUUGGGCGGGCUACGUGUGUGGAG   3 4  
P6-85 GGGGCGUGUUCGGGACGCCUUGUACGAACG   3   
P6-86 CGGGCGUCGACUGAAGUUUGAGGUGAAGGA 1  3   
P6-87 CGUGAUAGUUGUGCUGGCCGAUGGGUGGAC 1  3   
P6-88 CGCUGGUGGGUAGAGGUGUUUGUGUGCUGU 1  3 4  
P6-89 CGCCGUGCCAGCUCGGGACGGUGCGGCAGG   3   
P6-91 GUCGGCUGUUGACACGUGUAGUGUGGGUGG 1  3 4  
P6-94 CGCAGUGGAGGGCGAAUAAGAAUGUGACAG 1  3   
P6-95 CGGUGUGCGUGUGGGGACGCGUUCGUACAG    4 5 
P6-96 CGUGUUACGGCUGUGCUGGGUACAUCGGUG  2 3   
P6-98 GAUGAGGCCUCGGUAGUGUGGACAGUGCAG    4  
P6-99 GUGGCCGUGUGGGCAACGGAACAUGCCGUG   3 4  
P6-100 CGUGUUACGGCUGUGCUGGGUACAUCGGUG  2    
P6-101 CGGUAACGUGGCCUUAGGGCAGGAGGCUG  2 3   
P6-102 CGGCACGAUGUGUCUACCGCGGUGGGGC 1   4 5 
P6-103 GGUUGGACGUCGUCUGUGGGGGACUCGUGC  2   5 
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Table 1. Cont. 
Aptamer SEQUENCE (5′→3′) GROUP 
P7-4 GGCGUUGGUUUGUAUCGCGGCUUCGUGGGG     5 
P7-15 CGUCCCAAUUGACACGUGGCAGGGGAGCCG     5 
P7-49 CCGUGCGUGCAGUGGUUGGUCACGGCCUGG 1 2    
P7-90 CGGCCGUUGCUGGAGUGGUUGGCCGCAGUG 1 2    
P7-93 CAACUGCUCGUGUGUGGAGAGGGCGUGGCU   3 4  
P7-97 GACGUGUUCUGGCGUAUUGAGGGACGAUGG  2  4  
Sequence of the 30 nts-long variable RNA sequence of the selected aptamers, classified in groups according 
to common consensus sequences (colored). Shared nucleotides among different consensus motifs are depicted 
in italics, keeping the color corresponding to the consensus motif located in 5′. 
The results showed that around 35% of the tested aptamers promoted a significant reduction (>50%) 
in the relative HCV RNA levels (Figure 2). Four out of them—P6-89, P6-96, P6-103 and P7-49—reached 
inhibition values higher than 75%. An additional 30% also interfered with viral RNA synthesis at certain 
degree (30%–50%). These data argue for considering the CRE region as a potential therapeutic target. 
 
Figure 2. Inhibition of subgenomic HCV replicon replication in a hepatoma cell line. Huh-7 
cells supporting the autonomous replication of subgenomic HCV replicons were transfected 
with 5 μg of the indicated aptamer. Viral RNA was isolated and quantified as described in 
the Experimental Section. The bar chart shows the (+) strand HCV RNA levels normalized 
to the value obtained with the RNA80, an 80 nts-long unrelated RNA used as an internal 
control. Values are the mean of at least four independent experiments. 
Interestingly, though most of the aptamers showed more than one theoretical interacting site within 
the CRE region (Table 1), around 62% of them contained in their sequence consensus motifs targeting 
the apical loop (group 2) or the internal loop (group 3) of the 5BSL3.2 domain. This observation 
suggests that the 5BSL3.2 domain may act as a recruiting platform for nucleic acids, which is in good 
agreement with its involvement in a network of long distance intragenomic RNA-RNA interactions.  
It is noteworthy that the aptamers promoting a reduction above 75% in the relative HCV RNA amount 
contain sequence motifs belonging to groups 2, 3, and/or 5 (Figure 2 and Table 1). The target of these 
groups maps in critical regions for viral propagation, such as the apical and internal loops of the 
5BSL3.2 and the stem-loop containing the translation stop codon (Figure 1B) [32]. 
In summary, from this functional screening, four aptamers—P6-89, P6-96, P6-103, and P7-49—
emerged as potential tools for HCV detection and inhibition. 
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2.2. Biochemical Analysis of the Selected Aptamers 
Aptamers-mediated inhibition is directly related to their biochemical features, such as their  
three-dimensional folding and binding affinity to their target. Therefore, further efforts were focused 
on analyzing those properties. 
In silico structural analysis of the RNA molecules P6-89, P6-96, P6-103, and P7-49 was performed 
with the aim of identifying common structural motifs that could define a functional domain within  
the inhibitor RNA. The TurboFold tool was employed for that goal [39]. TurboFold is an iterative 
probabilistic method that uses a set of related sequences. It combines classical sequence comparison 
approaches and thermodynamic folding prediction to yield an estimation of the base pairing probabilities 
for each molecule. The use of this strategy reported a common secondary structure for the tested inhibitors 
(Figure 3), in which the constant sequences, corresponding to the ones used as primer binding site (PBS) 
during the selection process, appeared as single-stranded tails flanking the stem-loop containing the 
selected consensus motifs. These nucleotide motifs locate, at least partially, exposed in the apical loop 
(Figure 3). This folding gives the idea that the functional unit in the aptamer molecules is restricted to 
the stem-loop, which is used to efficiently interact with the target site in the CRE, in a similar way to 
that previously described for other regulatory RNA molecules [40]. This hypothesis prompted us to 
evaluate the binding ability of the aptamers to the CRE region. 
Binding affinity was analyzed by incubating a constant concentration of each 32P-internally labeled 
aptamer (~2 nM) with increasing amounts of the unlabeled construct CU [32], as detailed in the 
Experimental Section. This transcript CU bears the whole HCV CRE region from nucleotide 9181 
(upstream of the 5BSL3.1 domain) plus the whole 3′UTR [28]. The titration curve showed differential 
interaction efficiency for the different aptamers under study (see Figure 4 and Table 2). Thus, aptamers 
containing the consensus motif from the group 2 (P6-96, P6-103 and P7-49) exhibited an efficient 
binding ability, with low Kd values and complex formation yields above 50% (Figure 4 and Table 2). 
The molecule P6-103 emerged as the most efficient interacting partner for the CRE, with a Kd value of 
9.47 ± 3.49 nM and an extension complex formation of 1.04 ± 0.14. Interestingly, besides on bearing 
the group 2 consensus sequence, this aptamer contains the motif for group 5, which interacts with the 
translation stop codon. Finally, the variant P6-89, which targets the internal loop of the 5BSL3.2 domain 
(group 3), appeared as the less effective binder, with calculated Kd values in the range of low micromolar 
(see Figure 4 and Table 2). 
These results suggest that the selected aptamers P6-96, P6-103, and P7-49 may exert their anti-HCV 
activity by directly interacting with the CRE region. Subsequent analyses were aimed at elucidating 
the mechanism of action of the aptamers under study. 
Table 2. Binding constants for the selected aptamers.  
Aptamer Kd (nM) ± SD Bmax ± SD 
P6-89 1706.34 ± 230.15 n.d. 
P6-96 62.67 ± 0.74 1.15 ± 0.05 
P6-103 9.47 ± 3.49 1.04 ± 0.14 
P7-49 43.63 ± 16.22 1.07 ± 0.07 
Values are the mean of three independent trials ± the standard deviation (SD). Kd, dissociation constant;  
Bmax, final amplitude of the complex formation. n.d., non-determined. 
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Figure 3. Proposed secondary structure of P6-86, P6-96, P6-103 and P7-49 as determined by 
TurboFold software. Theoretical nucleotide motifs involved in the interaction with the CRE 
are colored according to the group they belong to, as indicated in Figure 1B. The constant 
and common sequences for all the aptamers tested, PBS1 and PBS2, are highlighted in grey. 
PBS, primer binding site. 
 
Figure 4. Binding assays of the aptamers P6-86, P6-96, P6-103, and P7-49 to the HCV CRE 
region. Graph shows the titration curve corresponding to the binding assays performed with 
the different aptamers under study. Internally 32P-labeled transcripts encompassing each of 
the tested aptamers were challenged with increasing amounts of their unlabeled interacting 
partner HCV-CRE194. Experiments were repeated at least three times and data were fitted 
to a non-linear equation for the calculation of the Kd value. 
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2.3. Aptamers Targeting the 5BSL3.2 Domain Compete with the Recruitment of the Viral  
RNA-Dependent RNA Polymerase by the CRE Region 
It has been described that the 5BSL3.2 domain binds to the viral NS5B protein [29,30]. Since some 
of the tested inhibitors harbor complementary sequence motifs to the 5BSL3.2 domain, it seemed 
reasonable to monitor whether the aptamers P6-89, P6-96, P6-103, and P7-49 could compete with the 
viral polymerase recruitment, as the replication inhibition mechanism. For that purpose, the aptamers 
were subjected to in vitro binding assays with the transcript HCV-CRE194 in the presence of the 
recombinant protein NS5BΔ21. Increasing concentrations of the aptamers under study were employed 
and the EC50 value was calculated. 
The results showed that molecules P6-89, P6-96, and P6-103 efficiently interfered with the binding 
of the NS5B protein to the HCV-CRE194 transcript in a concentration-dependent manner with EC50 
values in the nM range (Figure 5 and Table 3). Interestingly, the aptamer P7-49 barely showed a slight 
competitor activity (Figure 5). The addition of a non-related compound, such as glycogen, showed no 
binding inhibition activity (Figure 5), thus confirming the specificity of the observed competition. 
 
Figure 5. Competition of the interaction NS5BΔ21:CRE with the selected aptamers. The 
internally 32P-labeled HCV-CRE194 construct was incubated with a molar excess of the 
recombinant viral polymerase NS5BΔ21 and increasing concentrations of the aptamers under 
study, P6-86, P6-96, P6-103, and P7-49. Glycogen was used as a control of the competition 
reaction. Data were fitted to a non-linear equation to calculate the EC50 value. Values are 
the mean ± the standard deviation of four independent experiments. 
Table 3. EC50 values for the competition of the interaction NS5BΔ21: CRE with the aptamers 
P6-89, P6-96, P6-103, and P7-49. 
Aptamer EC50 (nM) a HCV-CRE194:NS5BΔ21 Complex (%) b 
P6-89 14.59 ± 1.11 5.09 ± 2.04 
P6-96 38.68 ± 5.63 0.00 ± 4.15 
P6-103 8.57 ± 0.58 11.98 ± 1.46 
P7-49 n.d. 75.37 ± 3.05 
a EC50 values were derived from the equation y = 100/(1 + 10(LogEC50−x)); b Data correspond to the highest 
concentration of inhibitor tested. Values are the mean of three independent assays ± the standard deviation 
(SD). n.d., non-determined. 
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These data demonstrate that the potential interaction of the aptamers P6-89, P6-96, and P6-103 with 
the CRE 5BSL3.2 domain interferes with the recruitment of the NS5B protein, which could be related 
to the observed anti-HCV effect. 
2.4. Effect of the Aptamers on HCV Translation 
Aptamers P6-89, P6-96, P6-103, and P7-49 contain sequence motifs complementary to functional 
RNA domains that are involved in the regulation of HCV translation, such as the 5BSL3.2 [22] and the 
stem-loop containing the stop codon. This observation led us to study their role on viral protein 
synthesis in cell culture translation assays. With that aim, a mixture containing the so-called transcripts 
cap-RLuc, Rep-FLuc, and a 20-fold molar excess of the aptamers or the non-related RNA80 was used 
to transfect Huh-7.5 cells. The molecule Rep-FLuc bears a dicistronic reporter subgenomic replicon 
construct in which the neo selectable marker is substituted by the reporter gene fluc from the Firefly 
spp., whose translation is controlled by the HCV IRES region [41] (Figure 6A). This strategy allows to 
measuring the IRES activity in the early post-transfection period (4–20 h). 
 
Figure 6. Effect on HCV translation of the aptamers P6-86, P6-96, P6-103, and P7-49  
in Huh-7 cells. (A) Schematic diagram showing the genetic organization of the reporter 
dicistronic replicon Rep-FLuc used in this study; (B) Huh-7 cells were co-transfected by 
electroporation with the RNA aptamers and 5.2 μg of a mixture containing the transcripts 
Rep-FLuc and cap-RLuc. HCV IRES activity was measured as the activity of FLuc  
protein and referred to that obtained for RLuc. Luciferase activity in the control reactions 
with the non-related RNA80 is established as 100%. Data points are the mean of  
three independent experiments. 
No effect was observed on protein synthesis for the inhibitors P6-96 and P6-103, suggesting that  
their potent inhibitory activity is mainly restricted to the replication step (Figure 6B). A significant 
increase in the FLuc activity was noted at early post-transfection times, when transfecting with the 
aptamer P6-89, but this effect was lately softened. Interestingly, the inhibitor P7-49 promoted a 
persistent enhancement (>50%, p < 0.05) in the IRES activity (Figure 6B), suggesting that this aptamer 
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could target a functional region in the viral RNA involved in the regulation of IRES-dependent 
translation. No significant changes (<10%, p < 0.05) were detected for the cap-dependent translation, 
pointing to a specific effect on HCV protein synthesis. 
Taken together, these data suggest that the tested inhibitors P6-96 and P6-103 specifically interfere 
with the HCV cycle mainly by blocking the replication step, while the molecules P6-89 and P7-49 exert 
a double role as HCV replication interfering agents and translational enhancers. 
2.5. Discussion 
Advances in clinical approaches for HCV detection and therapeutics are limited by the emergence  
of viral mutants. This phenomenon promotes the lack of effective antiviral sustained responses and  
false-negative tests. Therefore, it is desirable to search for novel targets that allow the development of 
efficient drugs and robust molecular diagnostic methodologies. Among the potential novel targets, the 
genomic RNA domains that play important roles in the consecution of essential viral processes are 
excellent candidates, which are worthy to be tested. In the context of both basic and applied research, the 
use of aptamers is recognized as a promising tool [5]. The present work describes the use of aptamers 
targeting highly conserved functional RNA domains of the HCV genome, provides important clues 
about their potential as antivirals and, more interestingly, highlights their use as molecular tools for 
understanding the functional role of the targeted RNA domains. 
We had previously reported the isolation of a collection of RNA aptamers targeting the highly 
conserved CRE region of the HCV genome [32]. Interestingly, we found that two of these molecules 
directed against the functional 5BSL3.2 domain of the CRE were effective inhibitors of viral 
replication [34]. This work reports the extension of such findings to a complete collection of aptamers. 
Our data confirm the potential of using the 5BS3.2 domain as an antiviral target. They also support its 
function in viral translation and in the recruitment of the viral RNA-dependent RNA polymerase. 
Further, the results point to the stem-loop containing the stop codon as a novel efficient antiviral target 
and open a new field to investigate the role of this element in the consecution of the viral cycle. 
The effectiveness of the CRE domain as a targeting region was evaluated. From the forty four 
molecules tested, 15 showed inhibition of HCV replication at rates higher than 50%. With the exception 
of variant P6-89, which targets the bulge of the 5BSL3.2, all of these efficient aptamers harbor sequence 
motifs complementary to the apical loop of the 5BSL3.2 domain. These results confirm the potential of 
the 5BSL3.2 as an anti-HCV target. 
Being the 5BSL3.2 a critical regulatory partner in the HCV IRES-dependent translation, some of the 
most efficient inhibitors of the viral replication were tested for their ability to affect the viral translation. 
Interestingly, two of the selected molecules, P6-89 and P7-49, promoted a significant increase in the 
IRES activity (Figure 6B). In the case of P6-89, this seems reasonable since it targets the internal loop of 
the 5BSL3.2. It has been previously reported that this motif acts as a negative partner of the HCV IRES 
function [22]. Therefore, it is likely that interfering with this activity can induce an enhancement of the 
IRES function. However, the role of P7-49 as an IRES-mediated translation inductor is surprising since 
this inhibitor theoretically interacts with the apical loop of the 5BSL3.2, which exerts its functionality 
mainly during viral replication [21]. It is plausible that P7-49 might interact with other essential domains 
of the CRE. In fact by using the folding software CoFold and RNAup, it was detected a major interacting 
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site in the apical loop of the 5BSL3.4 domain, involving the stop codon (Figure 7). This newly predicted 
targeted motif differs slightly from that one previously defined for the group 5 in the initial sequence and 
clustering analysis [32]. This finding could be related to the enhancement of the HCV IRES-dependent 
translation observed for the P7-49 aptamer (Figure 6B). By modifying the conformation of the 
environment surrounding the stop codon, the ribosomal recycling could be enhanced to improve the 
IRES-dependent translation rate [42]. The theoretical interaction model proposes the establishment of 
a kissing-loop contact involving the apical loop of the 5BSL3.4 and the apical loop of P7-49. This kind 
of interaction is widely used in many biological systems to initiate and regulate a variety of molecular 
processes [40]. Further, it is widely exploited by RNA aptamers to efficiently recognize their cognate 
target [43]. The hypothesis of an alternative interacting site to the apical loop of the 5BSL3.2 element  
is also sustained by the observation that P7-49 is not able to compete with the binding of the NS5B 
protein (Figure 5). However, one cannot rule out the possibility that the aptamer might bind to both 
sites promoting different effects, the combination of which yields the measured inhibition of the viral 
replication. Neither can it be ruled out that this apparent contradictory effect on translation (enhancer) 
and replication (inhibitor) is not so, and the latter is a consequence of the former. Further investigation 
to understand whether the increase in viral translation might lead to the inhibition of HCV replication, or 
whether this resulting antiviral activity is due to an independent mechanism of the effect on translation 
should be carried out. Work in this area is currently being accomplished in our laboratory, since this 
idea opens new fields to evaluate the real role of the stem-loop containing the stop codon in the viral 
cycle, and for that purpose, P7-49 could be used as a novel molecular tool. In addition to the measured 
replication inhibition that reflects its potential as an anti-HCV molecule, the understanding of its 
mechanism of inhibition might yield a still unexplored anti-HCV strategy. 
Finally, neither P6-96 nor P6-103 promoted any variation in the IRES activity (Figure 6B), which is 
consistent with the fact that both inhibitors bear complementary sequences to the apical loop of the 
5BSL3.2 element. Accordingly, they efficiently compete with the recruitment of the viral RNA polymerase 
(Figure 5), which could be directly related to their mechanism of action [34]. 
 
Figure 7. Theoretical model for the interaction between the 5BSL4 domain and the P7-49 
RNA aptamer. CoFold and RNAup software were used to predict the nucleotides involved 
in the binding between the 5BSL4 stem-loop and the P7-49 aptamer. Residues proposed to 
initiate the kissing-loop interaction are boxed. Nucleotides belonging to groups 1 and 2 are 
colored as indicated in Figure 2. PBS, primer binding site. 
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In summary, this study provides evidences for the development of molecular tools based on aptamers 
with the aim of elucidating multiple aspects of the viral biology. From a clinical point of view, the design 
of alternative therapeutic strategies combining several antiviral molecules with different activities  
and specificities is also a feasible option that is gaining increasing support in recent years. Therefore, 
aptamers can be considered as multivalent partners in the Virology lab. 
3. Experimental Section 
3.1. Cell Lines and HCV Constructs 
The human hepatoma cell line derivative Huh-7.5 are highly permissive for the initiation of HCV 
replication since they bear mutational inactivation of the retinoic acid-inducible gene I (RIG-I) [44].  
Cell monolayers were maintained in high glucose Dulbecco’s modified Eagle medium (DMEM) 
(Gibco by Thermo Fisher Scientific, Waltham, MA, USA) with 10% heat-inactivated fetal bovine serum 
(Invitrogen by Thermo Fisher Scientific, Carlsbad, CA, USA), 1 mM sodium piruvate (Sigma-Aldrich 
Chemie, Steinheim, Germany) and 0.1 mM of non-essential aminoacids, NEAA, in MEM (Gibco by 
Thermo Fisher Scientific), at 37 °C in a 5% CO2 atmosphere. 
Culture of the human hepatoma cell line Huh-7 NS3-3′ET supporting a subgenomic HCV replicon 
was carried out with DMEM-high glucose supplemented with 20% heat-inactivated fetal bovine serum,  
1 mM sodium piruvate and 0.5 mg/mL of G-418 (Sigma-Aldrich Chemie) [38]. The subgenomic replicon 
carries the HCV IRES of genotype 1b, followed by the neomycin phosphotransferase gene (neo), the 
EMCV IRES, the coding sequence for non-structural HCV proteins (NS3-NS5) and the HCV 3′UTR [36]. 
3.2. DNA Templates and RNA Synthesis 
DNA templates encoding the aptamer sequences were obtained by amplification as previously 
described [33]. The HCV-CRE194 DNA was obtained by SalI digestion of the plasmid construct  
pUC18-T7HCV9181-9371, as reported [33]. DNA templates for the synthesis of the non-related RNA80 
and cap-RLuc were constructed as specified in [37,45]. For the synthesis of the HCV subgenomic 
replicon system I389FLucNS3-3′ET, the plasmid pFK-I389FLucNS3-3′ET containing two cell-culture 
adaptive mutations in NS3 and one in NS5A, was restricted with SpeI. The RNA CU, bearing the CRE 
plus the whole HCV 3′UTR, was obtained as reported [28] for the binding assays. 
The purified DNA molecules were used for in vitro RNA synthesis with the TranscriptAid T7 high 
yield transcription kit (Thermo Fisher Scientific), following the manufacturer instructions. Transcripts 
were purified as previously described [26]. RNA quality was monitored by UV spectrophotometry 
(NanoDrop by Thermo Scientific, Wilmington, DE, USA) and denaturing agarose-formaldehyde or 
urea-polyacrylamide gel electrophoresis. 
3.3. Cell Transfection 
Inhibitory activity of the RNA aptamers on HCV replication was assayed in the cell line Huh-7  
NS3-3′ET as reported before [33,38]. Briefly, 48 h before transfection, ~90,000 cells were seeded onto 
24-well plates in culture medium. An amount of 5 µg of each RNA aptamer or the non-related RNA80 
was used for cell transfection using TransFectin™ lipid reagent (Bio-Rad, Hercules, CA, USA). Cells 
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were harvested 18 h after transfection and subjected to subsequent analyses. Each transfection assay 
was performed in triplicate. 
The effect of the aptamers on HCV translation was evaluated in Huh-7.5 cells. This cell line  
was transiently co-transfected with the reporter dicistronic subgenomic HCV replicon transcript, 
I389FLucNS3-3′ET, and the corresponding RNA aptamers or the RNA80. In addition, the reporter  
cap-RLuc transcript was included as internal transfection control. Cell were essentially electroporated as 
described [41], with minor variations. Briefly, monolayers of Huh-7.5 cells were trypsinized, counted 
and diluted to reach a concentration of 107 cells/mL in Cytomix [46] supplemented with 2 mM ATP, 
15 mM glutathione (Sigma-Aldrich Chemie) and 1.25% DMSO (Sigma-Aldrich Chemie). A mixture 
containing 5 µg of the subgenomic replicon construct, 200 ng of the cap-RLuc and 1 µg of each aptamer 
was incubated with the cell suspension on ice for 5 min. Electroporation was carried out at 1200 µF and 
270 V in a cuvette with a gap width of 0.4 cm, using a BTX ECM 630 electroporation system (BTX ECM® 
630, Holliston, MA, USA). Cells were seeded onto 6-well plates with 4 mL of DMEM and 1.25% 
DMSO and harvested at 4 and 20 h post-transfection for Firefly and Renilla luciferase measurements. 
3.4. Quantification of the HCV RNA Replicon 
Intracellular relative HCV RNA amount was quantified by qRT-PCR as previously reported [38]. 
Briefly, total RNA was extracted with Trizol reagent (Invitrogen by Thermo Fisher Scientific) following 
the manufacturer’s instructions. Fifty ng of the purified RNA were then reverse transcribed with the 
High capacity cDNA reverse transcription kit (Applied Biosystems by Thermo Fisher Scientific) using 
random primers. A fraction of the extension reaction was employed for quantitative PCR with the 
SsoFast™ Evagreen® supermix (Bio-Rad) and amplified over 40 cycles with specific oligonucleotides 
targeting the IRES region (C-149 and C-342) [47]. qRT-PCR of the mRNA encoding for the  
human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) was performed in parallel for relative 
quantification using the primers previously described (hGAPDH_Fw and hGAPDH_Rev) [48]. 
3.5. Binding Assays 
RNA aptamer:CRE binding efficiency was monitored by incubation of 20 fmol of the internally 
labeled 32P aptamer with increasing amounts (0–1 pmol) of the unlabeled target RNA CU. RNA 
molecules were independently denatured by incubation at 95 °C during 2 min and then chilled on ice  
for 15 min. Reactions were initiated by mixing both RNA molecules in the presence of binding buffer 
(25 mM Tris-HCl pH 7.5, 300 mM KCl, 1 mM MgCl2). Complex formation proceeded during 15 min 
at 37 °C and the resulting products were loaded in 8% native polyacrylamide gels supplemented  
with MgCl2 2 mM, in TBM buffer (45 mM Tris-HCl pH 8.3, 43 mM boric acid, 0.1 mM MgCl2). 
Electrophoresis proceeded at 12 mA and 4 °C during 3 h. Gels were then dried and further scanned  
using a Storm 820 PhosphorImager (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Analysis 
was accomplished with the ImageQuant v5.2 software (Molecular Dynamics, Sunnyvale, CA, USA). 
Dissociation constants Kd were calculated with the Sigma Plot v8.0 software (Systat Software Inc.,  
San José, CA, USA) and fitted to the equation y = (Bmax × x)/(Kd + x), where y is the percentage of bound 
aptamer, Bmax is the amplitude of the reaction, and x is the concentration of the substrate RNA CU [34]. 
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3.6. Aptamer Competition with the Binding of the NS5BΔ21 to the HCV-CRE194 
Recombinant viral RNA polymerase NS5BΔ21 was obtained as reported [34] and used for competition 
binding assays with the selected aptamers P6-89, P6-96, P6-103 and P7-49 [34]. RNA molecules were 
all independently denatured and folded as noted above before initiating the binding reactions. Fifty fmol 
of the 32P-internally-labelled HCV-CRE194 transcript were mixed with a 10-fold excess of the NS5BΔ21 
in competition buffer (5 mM HEPES pH 7.9, 2 mM MgCl2, 25 mM KCl). This interaction was competed 
with increasing amounts of the selected aptamers or a non-related molecule, the glycogen (Ambion by 
Life Technologies). Binding reactions were performed at 37 °C during 30 min. They were then diluted 
in the competition buffer and applied to 0.45 µm nitrocellulose membranes (GE Healthcare). Filters 
were previously presoaked in the competition buffer and assembled in a dot blot apparatus (Bio-Dot 
Apparatus, Bio-Rad). Samples were filtered under vacuum. Membranes were dried, scanned, and analyzed 
as indicated above. The EC50 values were calculated from the equation y = ymax/(1 + 10(LogEC50−x)), where 
y is the complex ratio, ymax is the maximum binding of the HCV-CRE194 RNA to the NS5BΔ21 protein, 
x is the aptamer concentration and EC50 the aptamer concentration that produces 50% of the maximum 
observed effect. 
3.7. Luciferase Assays 
Firefly and Renilla luciferase activities were determined with the Dual-Luciferase reporter assay 
system (Promega, Madison, WI, USA). All experiments were performed in triplicate and data are shown 
as normalized mean values ± standard deviation. 
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